)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Xilio Therapeutics (XLO) investor relations material
Xilio Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary14 Aug, 2025
Executive summary
Reported net loss of $15.8 million for Q2 2025, compared to $13.9 million in Q2 2024, and $29.1 million for the six months ended June 30, 2025, compared to $31.1 million in the prior year period.
Collaboration and license revenue rose to $8.1 million in Q2 2025 from $2.4 million in Q2 2024, driven by new agreements with AbbVie and Gilead.
Cash and cash equivalents totaled $121.6 million as of June 30, 2025, up from $55.3 million at December 31, 2024, expected to fund operations through Q3 2026.
Closed a $50 million follow-on public offering in June 2025, with potential for up to $100 million in additional proceeds from warrant exercises by 2026.
Reported updated Phase 2 data for vilastobart showing deep, durable responses and improved safety in anti-CTLA-4 combination therapy for metastatic MSS colorectal cancer, with further data expected in 2026.
Financial highlights
Q2 2025 revenue: $8.1 million, up $5.7 million year-over-year; six-month revenue: $11.0 million, up $8.7 million year-over-year.
Research and development expenses increased to $15.3 million in Q2 2025 (up $4.1 million year-over-year), driven by increased clinical and early-stage program activity.
General and administrative expenses rose to $7.1 million in Q2 2025 (up $1.3 million year-over-year), mainly due to higher professional and personnel costs.
Net loss per share for Q2 2025 was $0.16, compared to $0.24 in Q2 2024.
Weighted average shares outstanding (Q2 2025): 96.4 million, up from 57.8 million in Q2 2024 due to recent financings.
Outlook and guidance
Cash runway expected through the end of Q3 2026 based on current operating plans.
Additional capital may be needed; potential sources include warrant exercises, milestone payments, equity offerings, or new partnerships.
Ongoing clinical development for vilastobart and XTX301, with further data expected in 2026.
Plans to nominate development candidates for PSMA, CLDN18.2, and STEAP1 masked T cell engager programs between Q3 2025 and H1 2026.
Anticipates submitting IND applications for at least two masked T cell engager programs in 2027.
When will Xilio report additional Phase 2 data for vilastobart?
Discuss the design of Xilio's masked T cell engagers.
Explain the reasons for the increase in R&D expenses.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Xilio Therapeutics earnings date
Q3 20256 Nov, 2025
Next Xilio Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm focusing on discovering and developing tumor-activated immuno-oncology therapies. It focuses on creating treatments that are activated in the tumor environment, aiming to enhance the efficacy of immuno-oncology treatments while minimizing side effects. The company's portfolio includes a checkpoint inhibitor program with XTX101, an anti-CTLA-4 monoclonal antibody, alongside cytokine programs featuring XTX202 (a tumor-activated IL-2) and XTX301 (an engineered IL-12 molecule). The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage